Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol in Crohn's Disease (COSPAR II)
NCT00356408Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2007
- Primary completion
- Feb 2010
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoint: Occurrence of at Least One Treatment-emergent Adverse Event at 122 weeks. Started Jan 2007; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00356408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00356408.